336 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22664 | Stage IV NSCLC. Progression Under or after platinium regimen | Thierry Berghmans | Multiple | Novocure Gmbh | LUNAR | Trial closed | LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields(TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (avis 09/04/19) | 3 | 3 | ||
| 29765 | Bogdan Grigoriu | Lung | AbbVie | M18-868 | Trial open for recruitment | A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868) | Bogdan.Grigoriu@hubruxelles.be | 3 | 3 | ||
| 29430 | Have a confirmed diagnosis of MF ; Require therapy for MF in the opinion of the Investigator and are eligible for treatment with ruxolitinib ; Have DIPSS risk category Intermediate-1 or higher | Néoplasme myéloprolifératif (MPN) | Constellation | Manifest-2 | Trial closed | A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (Manifest-2) | 3 | 3 | |||
| 29411 | Nuria Kotecki | Multiple | MonTa Biosciences Aps | MBS8-101 | Trial open for recruitment | A phase I, multicenter, open-label, dose escalation study to determine the safety and preliminary efficacy of MBS8(1V270) administered intravenously to cancer patients with advanced solid tumours (MBS8-101) | Nuria.Kotecki@hubruxelles.be | 1 | 1 | ||
| 26201 | 1st line/ >= 60 years old and ineligible for autologous transplant/ Ann Arbor stage II-IV | Marie Maerevoet | Non-Hodgkin lymphoma | Lysarc | MCL-R2 Elderly | Trial closed for recruitment | Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma | marie.maerevoet@hubruxelles.be | 3 | 3 | |
| 22660 | 3rd to 5th line, FISH+ (IHC ++/+++), prior trastu/pertu &TDM1 | Philippe Aftimos | Breast | Merus | MCLA-128-CL02 | Trial closed | Phase 2 study of MCLA-128-CL02 Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive | philippe.aftimos@hubruxelles.be | 2 | 2 | |
| 29447 | Mariana Brandao | Multiple | Merus | MCLA-129-CL01 | Trial open for recruitment | Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors | mariana.brandao@hubruxelles.be | 1/2 | 1 | ||
| 22669 | Metastatic, Biopsy mandatory | Christiane Jungels | Multiple | Merus | MCLA-158-CL01 | Trial open for recruitment | Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22979 | - relapsed or refractory follicular NHL grade 1-2-3a - has received at least 1 prior line of therapy - at least 1 lymph node of at least 1.5cm or 1 ectra nodal lesion > 1cm - QTcF < 450 msec |
Marie Maerevoet | Multiple | MEI Pharma | ME-401-003 (TIDAL) | Trial closed | A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 28450 | Laura Polastro | Uterus | Merck | Merck - MS200647_0017 - TRAP0017 | Trial closed | A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing Chemotherapy | laura.polastro@hubruxelles.be | 2 | 2 | ||
| 22748 | Metastatic. RECIST v1.1 | Thierry Gil | Kidney | UCL St Luc | METASUN UCL-ONCO 2012-09 | Trial open for recruitment | A proof of concept study to evaluate the use of metabonomics and lipidomics in predicting toxicity and efficacy of anti-VEGF therapy in patients with metastatic clear cell renal cell carcinoma | thierry.gil@hubruxelles.be | |||
| 29427 | Newly diagnosed subjects eligible for high dose therapy and autologous stem cell transplantation | Nathalie Meuleman | Myeloma | IFM | MIDAS | Trial closed for recruitment | MInimal residual Disease Adapted Strategy: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group (IFM) (MIDAS ; IFM2020-02) | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 28577 | Martine Piccart | Breast | EORTC | MINDACT | Trial closed | Dissecting the pathways of endrocrine and chemotherapy resistance in breast cancer : A translational research project of the EORTC 10041/BIG 3-04 Mindact clinical trial (1550-BCG) | martine.piccart@hubruxelles.be | ||||
| 22815 | Recurrent or persistent or metastatic tumor | Ahmad Hussein Awada | Multiple | MSD (Merck Sharp & Dohme) | MK-3475-012 | Trial closed | A phase Ib multi-cohort study of MK-3475 in subjects with advanced solid tumors | ahmad.awada@hubruxelles.be | 1 | 1 |